William Young - Vertex Pharmaceuticals Independent Director
| VRTX Stock | USD 400.76 0.00 0.00% |
Director
Mr. William D. Young is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Young is a Senior Advisor with Blackstone Life Sciences . Mr. Young joined Clarus Ventures, a life sciences VC firm, in 2010. Prior to Clarus Ventures, Mr. Young served from 1999 until June 2009 as the Chairman and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company acquired by Laboratory Corporation of America in June 2009. From 1980 to 1999, Mr. Young was employed at Genentech, Inc. in positions of increasing responsibility, including as Chief Operating Officer from 1997 to 1999, where he was responsible for all product development, manufacturing and commercial functions. Prior to joining Genentech, Mr. Young was with Eli Lilly Co. for 14 years. Mr. Young currently serves as the Chairman of the Board of Directors of NanoString Technologies, Inc., and as a member of the Board of Directors of Theravance BioPharma Inc. Mr. Young retired from BioMarin Pharmaceutical Inc.s Board of Directors in November 2015 and as Biogens Chairman of the Board in June 2014. Mr. Young holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from Indiana University and an Honorary Doctorate in Engineering from Purdue University. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology. since 2014.
| Age | 73 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 50 Northern Avenue, Boston, MA, United States, 02210 |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
William Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Young against Vertex Pharmaceuticals stock is an integral part of due diligence when investing in Vertex Pharmaceuticals. William Young insider activity provides valuable insight into whether Vertex Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Vertex Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vertex Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Young over a month ago Disposition of 4608 shares by William Young of Smart Sand at 1.9 subject to Rule 16b-3 | ||
William Young over a year ago Acquisition by William Young of 10245 shares of Smart Sand subject to Rule 16b-3 |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Levy | Madrigal Pharmaceuticals | 60 | |
| Philip Ranker | Moderna | 53 | |
| Charles Baker | Regeneron Pharmaceuticals | 84 | |
| Gil Price | Sarepta Therapeutics | 58 | |
| Michael Bonney | Alnylam Pharmaceuticals | 59 | |
| Nancy Phelan | Moderna | 48 | |
| Anthony Chase | Sarepta Therapeutics | 60 | |
| Pablo Cagnoni | Crispr Therapeutics AG | 55 | |
| Kathy Rouan | Viking Therapeutics | 56 | |
| Bruce Kovner | Madrigal Pharmaceuticals | 69 | |
| David Milligan | Madrigal Pharmaceuticals | 77 | |
| Frank Verwiel | Intellia Therapeutics | 55 | |
| Adam Koppel | PTC Therapeutics | 45 | |
| David Southwell | PTC Therapeutics | 57 | |
| Kenneth Bate | Madrigal Pharmaceuticals | 67 | |
| Philippe Calais | Moderna | N/A | |
| Claude Nicaise | Sarepta Therapeutics | 65 | |
| Kurt Emster | Crispr Therapeutics AG | 51 | |
| Kathleen Behrens | Sarepta Therapeutics | 65 | |
| Carl Gordon | Intellia Therapeutics | 52 | |
| Stephen Webster | Viking Therapeutics | 57 | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | ||
| Jonathan JD, Executive Officer | ||
| Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer | ||
| Stephanie Franklin, Senior Officer | ||
| Michael Parini, Executive Vice President and Chief Legal Officer | ||
| Alan Garber, Independent Director | ||
| Joshua Boger, Executive Director and Chairman of Science and Technology Committee | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Jeffrey MD, Executive Chairman | ||
| Nina Devlin, Senior Officer | ||
| MD FASN, President CEO | ||
| Stuart BSc, Executive COO | ||
| John Gray, Senior Vice President Genetic Therapies | ||
| Margaret McGlynn, Independent Director | ||
| Sangeeta Bhatia, Director | ||
| Kristen CPA, Senior Officer | ||
| Terrence Kearney, Independent Director | ||
| Ian Smith, CFO, Executive Vice President | ||
| Kristen Ambrose, Tax, Accounting | ||
| Paul Silva, Senior Vice President Corporate Controller | ||
| David Altshuler, Independent Director | ||
| Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development | ||
| Elaine Ullian, Co-Lead Independent Director | ||
| Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value | ||
| David Greenway, Director | ||
| Charles Wagner, CFO, Executive Vice President | ||
| Ourania Tatsis, Ex Officer | ||
| Amit JD, Executive Officer | ||
| Bruce Sachs, Co-Lead Independent Director | ||
| Susie Lisa, Senior Relations | ||
| Lloyd Carney, Independent Director | ||
| Michael Partridge, Vice President - Investor Relations | ||
| Yuchun Lee, Independent Director | ||
| Kimberly White, Senior Vice President and Chief Communications Officer | ||
| Stuart Arbuckle, Chief Commercial Officer and Executive VP | ||
| Thomas Graney, CFO, Senior Vice President | ||
| Charles Milstein, Executive Vice President Chief Legal and Administrative Officer | ||
| Jeffrey Leiden, Chairman of the Board and Presidentident, CEO |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 94.18 B | ||||
| Shares Outstanding | 258.46 M | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 97.29 % | ||||
| Number Of Shares Shorted | 3.98 M | ||||
| Price To Earning | 24.57 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.88 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.